It is critical to rapidly identify molecules/peptides/proteins that can block the development and/or spreading of the 2019 Novel Coronavirus (SARS-CoV-2) and stop Covid-19 related disease. Computational methods (in silico) can quickly screen interactions of existing compounds with Covid-19 targets, but novel methods are needed to get high success rates in the (pre-)clinical phases. In addition, experimental validation of lead compounds is needed to benchmark the in silico hits.
Focus areas: COVID-19
Reward: Up to 1.000.000 Euros for the top-ranked team that experimentally screens combinations of FDA-approved compounds and demonstrates synergistic effects